Workflow
CNS Pharmaceuticals(CNSP)
icon
Search documents
CNS Pharmaceuticals(CNSP) - 2020 Q2 - Quarterly Report
2020-08-10 20:05
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CNSP The NASDAQ Stock Market LLC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to____ ...
CNS Pharmaceuticals(CNSP) - 2020 Q1 - Quarterly Report
2020-05-15 20:14
Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CNSP The NASDAQ Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to___ ...
CNS Pharmaceuticals(CNSP) - 2019 Q4 - Earnings Call Transcript
2020-03-12 23:38
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations John Climaco - Chief Executive Officer Chris Downs - Chief Financial Officer Conference Call Participants Operator Welcome to the CNS Pharm Business Update Conference Call. At this time, all participants are in listen only mode. Following management's prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is ...
CNS Pharmaceuticals(CNSP) - 2019 Q4 - Annual Report
2020-03-12 20:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (St ...
CNS Pharmaceuticals(CNSP) - 2019 Q3 - Quarterly Report
2019-12-20 21:02
Table of Contents Nevada 82-2318545 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CNSP The NASDAQ Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION R ...